Using Mobile Technology to Reduce Stress in Caregivers of Persons with Dementia. A Scalable Solution to A Growing Problem

PROJECT SUMMARY: Using the NIA 2-year R21 grant mechanisms, the proposed study will examine the feasibility (markers of acceptability and demand), and proof of concept of the consumer based mobile mindfulness application Calm in decreasing stress,

emotional distress and sleep dysfunction in heterogeneous, geographically diverse, stress caregivers of individuals with ADRD. Calm teaches fundamentals of mindfulness and uses evidence based behavioral principles to engage caregivers in sustained practice (>10 min/day) with minimal time commitment, when it is convenient for them, without the need of

travel or of a trained provider. To achieve our aims, we will conduct a single blind, pilot, feasibility, proof of concept RCT of CALM (12 weeks, > 10 minutes daily practice) versus an attention placebo time and dose matched podcast control (POD; 12 weeks, >10 minutes daily listening). Assessments will be conducted at baseline, post program (12 weeks

later) and at 20 weeks follow-up. Caregivers will also complete weekly assessments. Our team is well positioned to conduct this study with specific experience with mobile applications including Calm; intervention development,

feasibility testing and clinical trials; ADRD caregivers; recruitment of national, geographically diverse samples; R21 grant

proposals. At the end of the 2-year period of this R21 we will have clear evidence of the feasibility of study procedures,

randomization, acceptability, credibility, adherence, ability to retain and recruit as well as its proof of concepts in reducing

stress in caregivers of people with ADRD. Results from this R21 study will be used to apply for funding to conduct a fully powered efficacy RCT, if set benchmarks are met (see Table in the Research Strategy), through an R01. The goal is dissemination and implementation of Calm to reduce stress, emotional dysfunction, and sleep difficulties among all

caregivers of individuals with ADRD.